June 2, 2022 02:02 PM EDT
Pharma
Coronavirus
Law

Pfiz­er, like Mod­er­na, fires back at Al­ny­lam suit over Covid-19 vac­cine patents

Paul Schloesser

Associate Editor

In the lat­est de­vel­op­ment over al­leged patent in­fringe­ment re­lat­ed to Pfiz­er’s and Mod­er­na’s mR­NA vac­cines for Covid-19, Pfiz­er is step­ping up to the plate and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times